Darryl P. Toth
Windsor, ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study.
Journal: American journal of clinical dermatology
Published: December 23, 2025
Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents.
Journal: The New England journal of medicine
Published: November 05, 2025
52-week ivarmacitinib in moderate-to-severe atopic dermatitis: A phase 3 trial.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: October 28, 2025
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.
Journal: Journal of the American Academy of Dermatology
Published: September 20, 2023
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
Journal: JAMA dermatology
Published: May 03, 2023
Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial.
Journal: American journal of clinical dermatology
Published: October 16, 2022
Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies.
Journal: Journal of the American Academy of Dermatology
Published: March 23, 2022
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial.
Journal: Journal of the American Academy of Dermatology
Published: December 31, 2021
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
Journal: Journal of the American Academy of Dermatology
Published: November 06, 2020
Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.
Journal: The British journal of dermatology
Published: September 25, 2020
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Published: September 05, 2019
Last Updated: 09/26/2026